Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Annals of Surgery|February 25, 2021
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic CancerDaniel Brock Hewitt, Nicholas Nissen, Hassan Hatoum, et al.
Cancers|February 13, 2026
Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001Elena Gabriela Chiorean, Sheela R Damle, David B Zhen, et al.
JCO Oncology Practice|December 15, 2025
Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-AnalysisAmy H Huang, Gin Yi Lee, Chuan Angel Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal CancerAndrew G Hill, Michael P Findlay, Matthew E Burge, et al.
The Oncologist|September 20, 2022
KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal AdenocarcinomasAdam C Diehl, Lindsay M Hannan, David B Zhen, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlatesJohn B Liao, William R Gwin, Renata R Urban, et al.
Learning Health Systems|January 17, 2025
The power of personas: Exploring an innovative model for understanding stakeholder perspectives in an oncology learning health networkDylan J Cooper, Jessie Karten, Sarah E Hoffe, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 6, 2024
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaAndrew L Coveler, Matthew J Reilley, Mark Zalupski, et al.
The Lancet. Oncology|May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
Pageof 6